Orphan drugs in Switzerland
Switzerland has a workable route for medicines against rare diseases: orphan status, simplified authorisation, documentation protection and reimbursement paths that fit tiny patient numbers. Here is how it fits together, and where a Swiss holder is essential.
What counts as an orphan drug in Switzerland?
Swiss law recognises medicines for rare diseases as a distinct category, granted orphan status by Swissmedic on application. The criteria centre on a life-threatening or chronically debilitating condition affecting a small share of the population, and status can also follow from recognition as an orphan medicine by a comparable foreign authority.
The status is worth applying for even when the product is already an EU orphan medicine: it is what opens the simplified authorisation route in Switzerland and it supports the documentation protection that makes a small indication commercially defensible.
Important medicinal product for rare diseases
The Swiss legal term is wichtiges Arzneimittel für seltene Krankheiten, commonly abbreviated to orphan drug. Status is granted by Swissmedic, is applied for separately from the authorisation itself, and can be requested before the authorisation application is filed.
Which advantages does orphan status bring?
Orphan status does not lower the scientific bar; it changes what the bar is measured against. Swissmedic can accept a smaller evidence base where a larger one is impossible, and the administrative route is shorter.
- Simplified authorisation under Art. 14 HMG, with requirements proportionate to the available evidence.
- Documentation protection for rare disease products, which protects the dossier from being used by a competitor for a defined period.
- Fee relief in defined cases, which matters for a product with a handful of Swiss patients.
- Temporary authorisation where a serious condition has no alternative and the benefit is expected, with conditions attached.
- Scientific advice from Swissmedic before submission, which for a rare disease dossier is usually time well spent.
How do rare disease products get reimbursed?
The standard route is still the Spezialitätenliste at the Federal Office of Public Health, and the standard instruments still apply: an international price comparison and a therapeutic cross-comparison. For an orphan product the comparison is often thin, so the clinical argument and the choice of comparator carry more weight than in a crowded indication.
Outside the list, Swiss insurers can cover a medicine in an individual case under defined conditions, which is how many rare disease patients are treated before a listing exists. It is a bridge, not a business model: the cost per case is negotiated individually and the outcome is not predictable.
| Route | Who decides | When it fits |
|---|---|---|
| SL listing | Federal Office of Public Health | The goal for any product with recurring patients |
| Individual case cover | The patient's insurer | Bridge before listing, or outside the limitation |
| Temporary authorisation | Swissmedic | Serious condition, no alternative, benefit expected |
| Named patient supply | Treating physician, strict limits | Single patients, not commercialisation |
Why orphan products need a Swiss holder more than others
An orphan product typically has a few dozen Swiss patients, two or three treating centres and a high price per pack. The fixed cost of a Swiss affiliate is impossible to justify, and yet the regulatory duties are the same as for a mass-market product: a holder with a Swiss domicile, a reachable safety function, three language versions, batch release and a recall capability.
That is exactly the gap the holder model fills, and it is why rare disease companies are their most frequent clients. external MAH providers also distributes rare disease products in Switzerland in its own name, so the operational side is routine rather than theoretical.
For the Swiss orphan drug data and the authorised product list, see the sibling reference site swissorphanaccess.com.
Frequently asked questions
Does EU orphan designation automatically apply in Switzerland?
No, but it helps. Swiss orphan status is granted by Swissmedic on a separate application, and recognition by a comparable foreign authority is one of the ways to substantiate it. Plan the Swiss status application as its own small project before the authorisation submission.
Can we supply Swiss patients before authorisation?
In narrow circumstances, through the routes Swiss law provides for individual patients and for serious conditions without alternatives. These routes are patient-specific and documented; they are not a way to build a market ahead of an authorisation.
Is the Swiss price for orphan drugs lower than in the EU?
Not systematically. Swiss prices are derived from a reference country comparison and a therapeutic cross-comparison, and for orphan products with few comparators the result depends heavily on how the case is argued. High Swiss prices for rare disease products exist, and so do refused listings.
How many patients do we need for the business case to work?
With a service holder rather than an affiliate the break-even is remarkably low, because there is no Swiss headcount. External providers have run mandates with fewer than fifty patients in the country. The decisive variables are the price level and how much variation work the dossier generates.
Enquire about Swiss MAH support
Describe your product, dossier status and support needs. Enquiries reach the website operator at info@mahswitzerland.com. Provider qualifications, availability and contracts must be checked separately.
- Independent information portal
- Public Swiss sources, independent explanations, and enquiries about external specialist services.